KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) EBT Margin: 2009-2025

Historic EBT Margin for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to 61.81%.

  • Halozyme Therapeutics' EBT Margin rose 488.00% to 61.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 60.02%, marking a year-over-year increase of 934.00%. This contributed to the annual value of 54.87% for FY2024, which is 1287.00% up from last year.
  • Per Halozyme Therapeutics' latest filing, its EBT Margin stood at 61.81% for Q3 2025, which was down 1.77% from 62.92% recorded in Q2 2025.
  • Halozyme Therapeutics' EBT Margin's 5-year high stood at 67.07% during Q2 2021, with a 5-year trough of 19.70% in Q2 2022.
  • Moreover, its 3-year median value for EBT Margin was 50.89% (2024), whereas its average is 51.01%.
  • As far as peak fluctuations go, Halozyme Therapeutics' EBT Margin surged by 5,558bps in 2021, and later tumbled by 4,737bps in 2022.
  • Halozyme Therapeutics' EBT Margin (Quarterly) stood at 53.73% in 2021, then slumped by 1,473bps to 39.00% in 2022, then surged by 498bps to 43.98% in 2023, then surged by 1,582bps to 59.80% in 2024, then spiked by 488bps to 61.81% in 2025.
  • Its last three reported values are 61.81% in Q3 2025, 62.92% for Q2 2025, and 54.30% during Q1 2025.